Sara Loeffler, MD
Endocrinology, Diabetes & Metabolism · Westminster, MDNPI 1508181520
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,547 of the $138,092 with a category attached, or 90.9%. Lilly USA, LLC accounts for 96.8% of it on its own, with 26 other manufacturers making up the rest. Among endocrinology, diabetes & metabolism clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $384.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$134K
- Tandem Diabetes Care, Inc.$2K
- Medtronic$942
- Xeris Pharmaceuticals, Inc.$386
- Amgen$366
- Dexcom, Inc.$249
- plus $955 from 21 others
What the payments were for
- Speaking & faculty fees$125,54791%
- Travel & lodging$7,0115%
- Food & beverage$5,4564%
- Education$780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 257 | $133,622 |
| Tandem Diabetes Care, Inc. | 6 | $1,572 |
| Medtronic(2 entities) | 16 | $942 |
| Xeris Pharmaceuticals, Inc. | 17 | $386 |
| Amgen(2 entities) | 19 | $366 |
| Dexcom, Inc. | 3 | $249 |
| Sanofi-aventis U.S. LLC | 6 | $115 |
| Novo Nordisk | 4 | $101 |
| Corcept Therapeutics | 2 | $92 |
| Abbott | 5 | $89 |
| Amneal Pharmaceuticals LLC | 4 | $85 |
| Sanofi | 1 | $72 |
| AstraZeneca | 3 | $55 |
| Radius Health, Inc. | 2 | $38 |
| Cequr Corporation | 1 | $37 |
| Ascendis Pharma Endocrinology Inc | 1 | $36 |
| Boehringer Ingelheim | 2 | $34 |
| Rhythm Pharmaceuticals, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Acella Pharmaceuticals, LLC | 1 | $22 |
| AbbVie | 1 | $22 |
| Bayer | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Averitas Pharma Inc. | 1 | $16 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$127,547
- t:slim X2 Insulin Pump with Control-IQ$1,554
- MINIMED 780G$556
- RECORLEV$130
- TEPEZZA$124
- DEXCOM G6 TRANSMITTER$111
How this compares
$138,092 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 400 | $695,199 |
| MounjaroTirzepatide | 234 | $411,471 |
| JardianceEmpagliflozin | 192 | $272,355 |
| Tresiba Flextouch U-100Insulin Degludec | 171 | $130,584 |
| TrulicityDulaglutide | 53 | $112,582 |
| JanuviaSitagliptin Phosphate | 86 | $93,794 |
| FarxigaDapagliflozin Propanediol | 76 | $90,033 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $76,952 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $72,828 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $71,623 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $67,694 |
| TradjentaLinagliptin | 49 | $57,121 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 93 | $52,787 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 22 | $36,832 |
| Humalog Kwikpen U-200Insulin Lispro | 12 | $34,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $101 | $732,980452 claims |
| Lilly USA, LLCMounjaro, Trulicity | $133,622 | $524,053287 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Glyxambi, Synjardy Xr | $34 | $394,125291 claims |
| AstraZenecaFarxiga | $55 | $90,03376 claims |
| AbbVieSynthroid | $22 | $16,194175 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $85 | $4,533470 claims |
| Sanofi-aventis U.S. LLCAdmelog | $115 | $3,66412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Westminster
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Nicholas ArgentoLaurel$1.1M
- Romeu AzevedoCamp Springs$987K
- David BrownRockville$497K
- Philip LevinBaltimore$489K
- Helena RodbardRockville$468K
- Roy PhillipsBel Air$208K
- Eyob MakonnenAnnapolis$205K
- Jawaad KhokharGlen Burnie$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.